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Abstract
Hypoxia plays an important role in the resistance of tumour cells to chemotherapy. However, the exact mechanisms
underlying this process are not well understood. Moreover, according to the cell lines, hypoxia differently influences cell
death. The study of the effects of hypoxia on the apoptosis induced by 5 chemotherapeutic drugs in 7 cancer cell types
showed that hypoxia generally inhibited the drug-induced apoptosis. In most cases, the effect of hypoxia was the same for
all the drugs in one cell type. The expression profile of 93 genes involved in apoptosis as well as the protein level of BCL-2
family proteins were then investigated. In HepG2 cells that are strongly protected against cell death by hypoxia, hypoxia
decreased the abundance of nearly all the pro-apoptotic BCL-2 family proteins while none of them are decreased in A549
cells that are not protected against cell death by hypoxia. In HepG2 cells, hypoxia decreased NOXA and BAD abundance and
modified the electrophoretic mobility of BIMEL. BIM and NOXA are important mediators of etoposide-induced cell death in
HepG2 cells and the hypoxia-induced modification of these proteins abundance or post-translational modifications partly
account for chemoresistance. Finally, the modulation of the abundance and/or of the post-translational modifications of
most proteins of the BCL-2 family by hypoxia involves p53-dependent and –independent pathways and is cell type-
dependent. A better understanding of these cell-to-cell variations is crucial in order to overcome hypoxia-induced resistance
and to ameliorate cancer therapy.
Citation: Sermeus A, Genin M, Maincent A, Fransolet M, Notte A, et al. (2012) Hypoxia-Induced Modulation of Apoptosis and BCL-2 Family Proteins in Different
Cancer Cell Types. PLoS ONE 7(11): e47519. doi:10.1371/journal.pone.0047519
Editor: Elad Katz, University of Edinburgh, United Kingdom
Received June 4, 2012; Accepted September 12, 2012; Published November 5, 2012
Copyright:  2012 Sermeus et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: AS and AN are Research Fellow of FNRS (Fonds de la Recherche Scientifique, Belgium). MG and LL are supported by FRIA (Fonds pour la Recherche dans
l’Industrie et l’Agriculture, Belgium). HR is recipient of a FNRS-Te´le´vie grant. This article presents results of the Belgian Program on Interuniversity Poles of
Attraction initiated by the Belgian State, Prime Minister’s Office, Science Policy Programming. The responsibility is assumed by its authors. The funders had no role
in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: carine.michiels@fundp.ac.be
Introduction
Cancer is one of the main causes of death in developed
countries. Treatments often include the use of chemotherapies but
drug resistance is a common cause of treatment failure and
relapse. Most chemotherapeutic drugs induce cell death by
triggering apoptosis. Apoptosis is regulated by proteins of the
BCL-2 (B-cell lymphoma-2) family that mainly act at the
mitochondrial level. This family of proteins can be subdivided
into three categories according to the function and structure of the
proteins [1]. First, the BAX-like proteins, such as BAX (BCL-2
associated6 protein) and BAK (BCL-2 homologous antagonist/
killer), are death factors. Once activated, they oligomerise at the
mitochondria and induce mitochondrial outer membrane per-
meabilisation, which provokes cell death. The BCL-2-like proteins,
such as BCL-2, BCL-xL (B-cell lymphoma-extra large), BCL-w
and MCL-1 (myeloid cell leukaemia 1), are survival factors. They
form heterodimers with BAX/BAK and inhibit their action.
Finally, the BH3 (BCL-2 homology domain 3)-only proteins, such
as BID (BH3-interacting domain death agonist), BAD (BCL-2-
antagonist of cell death), BIM (BCL-2-interacting mediator of cell
death), BIK (BCL-2 interacting killer), PUMA (p53 upregulated
modulator of apoptosis) and NOXA, induce apoptosis by
neutralizing the antiapoptotic BCL-2-like molecules and, for some
of them, by directly activating BAX/BAK. In healthy cells, BH3-
only proteins are either not present or kept inactive or sequestered.
Following proapoptotic signals, they become transcriptionally
upregulated and/or post-translationally modified (and/or reloca-
lised) to gain their full proapoptotic function [1,2].
One of the main causes of resistance to chemotherapy-induced
apoptosis is p53 mutation. p53 is indeed a central player for the
induction of apoptosis in stressed cells [3,4] Another well-known
cause of resistance is tumour hypoxia [5]. The effects of hypoxia
on cancer cells are cell type dependent and differ according to the
intensity and the duration of the lack of O2. Severe and prolonged
hypoxia may initiate apoptosis or necrosis while mild hypoxia is
protective [6,7]. Indeed, mild hypoxia interferes with several
components of the apoptotic pathway at the transcriptional as well
as at the post-translational level.
Previous results from our group showed that hypoxia protects
tumour cells from apoptosis induced by chemotherapeutic agents.
Hypoxia protects HepG2 cells against etoposide-induced apoptosis
as well as MDA-MB231 cells against paclitaxel-induced apoptosis
[8,9,10]. However, in other cell types, hypoxia may have no effect
or even aggravate the apoptosis induced by chemotherapeutic
agents. It is for example the case for etoposide-induced apoptosis
of A549 and MCF-7 cells as well as for epirubicin-induced
apoptosis of MDA-MB231 cells [8,10]. These results have also
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e47519
underlined that cell responses to hypoxia is very complex,
involving different signal transduction pathways as well as several
transcription factors. Notably, the p53 transcription factor seems
to play an important role in the cell behaviour under hypoxia [8].
The aim of this work is to understand how hypoxia may differently
influence the chemotherapeutic drug-induced apoptosis in cancer
cells. Therefore, we first extended our previous observations using
7 cancer cell lines, originating from various organs and having
different p53 status, exposed to 5 apoptosis-inducing drugs used in
chemotherapy that target different cellular pathways. In most
cases, hypoxia partly prevented cell death and the effect of hypoxia
was the same for all the drugs in one cell type. Secondly, we
observed that hypoxia modulated the abundance of most proteins
of the BCL-2 family in a cell type-dependent manner. Thirdly, in
HepG2 cells that are protected by hypoxia against etoposide-
induced cell death, we observed a decrease in BAD and NOXA
protein level as well as a change in the electrophoretic mobility of
BIMEL (BIM extra long) in hypoxia-incubated cells. Results from
invalidation studies suggest that the combined loss of BIM and
NOXA during hypoxia at least in part accounted for chemore-
sistance.
Materials and Methods
Cell Culture and Hypoxia Incubation
Human hepatoma HepG2 cells, human lung carcinoma A549
cells, human breast adenocarcinoma MDA-MB231 cells, human
hepatoma Hep3B cells, human osteogenic sarcoma U2OS cells,
human colon adenocarcinoma HT-29 cells and human prostate
adenocarcinoma PC-3 cells (ATCC) were maintained in culture in
75-cm2 polystyrene flasks (Costar) with respectively D-MEM (low
glucose) (Gibco), MEM (Gibco), RPMI 1640 (Gibco), RPMI 1640
(Gibco) containing 50 U/ml penicillin and 50 mg/ml streptomycin
(Gibco), Mc Coy’s 5A medium (Gibco), RPMI 1640 (Gibco) and
F12 Kaighn’s medium (Gibco) containing 10% of FCS and
incubated under an atmosphere containing 5% CO2.
For hypoxia experiments, cells were incubated in serum-free
CO2-independent medium (Invitrogen) supplemented with
0.5 mM L-glutamine (Sigma) with or without etoposide (Sigma),
methotrexate (Sigma), paclitaxel (Molecular Probes), cisplatin
(Sigma) or camptothecin (Sigma) for 16 hours. The incubation
under hypoxia was performed in home-made incubators contain-
ing 99% N2 and 1% O2. The level of hypoxia in the medium in
our experimental conditions is 10 mm Hg of dissolved oxygen
within the medium. This level of hypoxia is achieved after about
10 min of incubation. PO2 level was measured using a dissolved
oxygen meter (Inolab Oxi 730) equipped with a Cellox 325 probe.
Normoxic control cells were incubated in the same conditions but
in normal atmosphere (21% O2).
siRNA Transfection
siGENOME SMARTpool human (Dharmacon; used at 50 nM)
BCL2L11 (BIM, M-004383-02), PMAIP1 (NOXA, M-005275-
03), BAD (M-003870-02) or TP53 (M-003329-03) were transfected
with the DharmaFECT1 transfection reagent (Dharmacon; used
at a 1:500 dilution). When combining BIM and NOXA siRNA,
each siRNA was used at 25 nM. The siGENOME RISC-Free
Control siRNA (D-001220-01, Dharmacon; used at 50 nM) or
siGENOME Non-Targeting siRNA Pool #1 (D-001206-13,
Dharmacon; used at 50 nM) were used as negative controls. Cells
were incubated for 24 hours with transfection medium and the
medium was then replaced by fresh medium with 10% of FCS. 6
hours later (or 30 hours later for BIM siRNA), cells were incubated
under hypoxia or normoxia with chemotherapeutic agents or not.
Subcellular Fractionation
Cells, seeded in 75-cm2 flasks, were harvested in saccharose M/
4 and homogenized by 3 strokes of a B plunger in a Dounce. The
homogenate was centrifuged 10 minutes at 1,418 g (Labofuge
400R Heraeus Instruments). The supernatant was recovered and
centrifuged at 81,085 g (Beckman L7-35, rotor 50 Ti) for
a duration dependent of the volume. The pellet was resuspended
in saccharose M/4 and named the MLP fraction. The supernatant
was concentrated by centrifugation in Amicon Ultra-4 tubes
(Millipore) and named the S fraction. All the samples were finally
homogenized by sonication.
Western Blot Analysis
Protein extraction was performed as described in [9]. Proteins
were separated by SDS-PAGE on 15% polyacrylamide gel, on
4–12% NuPAGE Bis-Tris gels with MES buffer (Invitrogen) or
on 3–8% NuPAGE Tris-Acetate gels (Invitrogen) and then
transferred to a PVDF membrane (Hybond-P, Amersham for
chemiluminescence detection or Immobilon-FL, Millipore for
fluorescence detection). Chemiluminescence detection was per-
formed as described in [11] using overnight incubation with
specific primary antibodies. For fluorescence detection, mem-
branes were blocked 1 hour at room temperature in Odyssey
blocking buffer (LI-COR) and then overnight at 4uC in Odyssey
blocking buffer with 0.1% Tween containing a specific antibody.
After 465 minutes washes in PBS-Tween 0.1%, the incubation
with the secondary antibody (goat anti-rabbit or anti-mouse
IRDye-labeled antibody, LI-COR, 1:10,000 dilution) was
performed for 1 hour in Odyssey blocking buffer with 0.1%
Tween followed by 4 washes of 5 minutes in PBS-Tween and 2
washes in PBS. The membrane was then dried 1 hour at 37uC
and scanned using Odyssey infrared imaging system (LI-COR).
Immunofluorescence Staining
HepG2 cells were seeded at 40,000 cells/well on glass cover
slides in 24-well plates. After incubation with or without etoposide
or paclitaxel, immunofluorescence staining was performed as
described in [11]. Primary antibody for alpha-tubulin staining was
mouse anti-alpha-tubulin (# T5186 Sigma) (1/100 dilution).
Alexa Fluor-647-conjugated anti-mouse IgG antibody (Molecular
Probes) was used at 1/1,000 dilution.
Caspase-3/7 Activity Assay
The fluorogenic substrate Ac-DEVD-AFC (BD Pharmingen)
was used to measure caspase-3/7 activity according to [12]. Cell
extracts were prepared as described in [13]. Cells were seeded in
25-cm2 flasks. The assay for caspase-3/7 activity was performed
according to [8] using 20 mg of extracts.
Lactate Dehydrogenase Release Assay
Lactate dehydrogenase (LDH) release was measured with the
‘‘Cytotoxicity Detection Kit’’ from Roche Applied Science as
described in [9]. The culture media from incubated cells were
removed and centrifuged to pellet the cell fragments and
apoptotic bodies. In order to lyse the cells, Triton X100 (Merck)
at 10% in PBS was added on this pellet as well as on the cells
remaining attached on the bottom of the wells. The percentage
LDH release was calculated as follows: [LDH activity in
medium (1) + LDH activity of cells fragments and apoptotic
bodies (2)]/[(1) + (2) + LDH activity of cells remaining in the
wells].
Effect of Hypoxia on BCL-2 Family Proteins
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Transient Transfection and Luciferase Assay
Cell transfection was performed in 24-well plates (50,000 cells
per well for HepG2 and MDA-MB231 cells; 30,000 for A549 cells;
and 40,000 for Hep3B cells) with SuperFect reagent (Qiagen).
923 ng (1385 ng for MDA-MB231 cells) of the reporter plasmid
pGL3-(PGK-HRE6)-tk-luc, which contains 6 HRE cis-elements
from the PGK gene linked to the thymidine kinase basal promoter
and to the firefly luciferase gene [14], were co-transfected with
577 ng (115 ng for MDA-MB231 cells) of normalization vector
(pCMVb vector coding for the b-galactosidase, Clontech) in
medium without serum for 6 hours (or 3 hours for Hep3B cells
before replacing the medium with fresh medium). Afterwards, cells
were incubated under hypoxia or normoxia for 16 hours. After
incubation, cells were lysed in Passive Lysis Buffer (Promega) and
b-galactosidase was assayed in parallel to the firefly luciferase
activity, assayed using the Luciferase Assay System (Promega).
Taqman Low Density Array
After the incubation, total RNA was extracted using TRI
Reagent Solution (Applied Biosystems). mRNA contained in 2 mg
total RNA was reverse transcribed using the ‘‘High Capacity
cDNA Reverse Transcription kit’’ from Applied Biosystems
according to the manufacturer’s instructions. 100 ng of retro-
transcribed total RNA in 50 ml were then mixed with 50 ml of the
‘‘Taqman Universal PCR master Mix’’ (Applied Biosystems) and
loaded into one of the 8 fill ports of the microfluidic array. ‘‘TLDA
Human Apoptosis Panel’’ are 384-well microfluidic cards that
contain assays for 96 human genes. They enable to perform 96
real-time PCR reactions simultaneously for 4 samples. mRNA
expression level was quantified using the threshold cycle method
with 18S as the reference gene.
RT Real-time-PCR for mRNA Quantification
After the incubation, total RNA was extracted using TRI
Reagent Solution (Applied Biosystems). mRNA contained in 2 mg
total RNA was reverse transcribed using SuperScript II Reverse
Transcriptase (Invitrogen). Forward and reverse primers sequences
are available in Table S1 and were designed using the Primer
Express 1.5 software (Applied Biosystem). Amplification reaction
assays contained 16 SYBRGreen PCR Master Mix (Applied
Biosystem) and primers (Applied Biosystems, 300 nM). RPL13A
was used as the reference gene for normalization and mRNA
expression level was quantified using the threshold cycle method.
Heatmap and Statistical Analyses
Heatmaps were generated with the data transformed in
logarithm base 2 of the results for TDLA (n= 1) and of the means
of three values for qRT-PCR results. Statistical analyses were
carried out with ANOVA 1 and Tukey’s multiple comparison tests
using GraphPad Prism.
Results
Hypoxia has Different Effects on Drug-induced Cell Death
in Different Cell Types
In order to obtain further insight of the mechanisms initiated by
hypoxia that lead to cancer cell resistance, we extended our
previous observations using other cancer cell lines originating from
various organs and having different p53 status and other
apoptosis-inducing chemotherapeutic drugs that target different
cellular pathways. The cell lines used are HepG2 (p53 wild-type
hepatoma cells), A549 (p53 wild-type lung carcinoma cells), U2-
OS (p53 wild-type osteogenic sarcoma cells), MDA-MB231 (p53
mutant breast adenocarcinoma cells), HT-29 (p53 mutant colon
adenocarcinoma cells), Hep3B (p53 null hepatoma cells), and PC-
3 (p53 null prostate adenocarcinoma cells) cells. The chemother-
apeutic agents chosen are etoposide (a topoisomerase II inhibitor),
methotrexate (a DNA and RNA synthesis inhibitor), paclitaxel (an
inhibitor of microtubule dynamics), cisplatin (an alkylating agent)
and camptothecin (a topoisomerase I inhibitor).
First, the concentration of drug to use on each cell type was
chosen by assaying caspase-3/7 activity after 16 hours incubation
with the drugs. In each case, a concentration inducing moderate
apoptosis was chosen. For the agents inducing no caspase activity,
their overall toxicity was evaluated by measuring lactate de-
hydrogenase (LDH) release 40 hours after incubation with the
agents. Once the concentrations were chosen, the effect of hypoxia
(1% O2) on the cell death induced by each agent in each cell type
was monitored by the two same techniques (Figure 1).
We observed that, in general, the p53 mutated or null cells are
more difficult to kill than the p53 wild-type cells. In most cases, the
effect of hypoxia on cell death was the same for all molecules in
one cell type. However this effect varied according to the cell type.
We observed also that hypoxia had more often a protective effect
against cell death than an aggravating effect. For example,
hypoxia protected HepG2 and MDA-MB231 cells against the cell
death induced by all the molecules tested while we observed no
effect or an aggravation of drug-induced cell death by hypoxia in
A549 and Hep3B cells. Hypoxia can therefore protect p53 wild-
type as well as p53 mutated cells. Altogether, these results
generated a matrix of data about the effect of hypoxia on the
apoptosis induced by 5 molecules in 7 cell types (Table 1). The
results showed that the effect of hypoxia is different according to
the cell type but constant for all the drugs on one cell type. To the
best of our knowledge, this observation has never been made
before.
Expression Profile of mRNA and Proteins Involved in
Apoptosis in Different Cell Types
In order to understand why hypoxia protected some cell lines
against drug-induced death but not others, we selected four cell
lines harbouring different p53 status and for which the effect of
hypoxia is different: HepG2, A549, MDA-MB231 and Hep3B
cells. We used etoposide as cell death inducer since it is powerful in
all four cell lines and its mode of action is well known. The effect of
hypoxia on the paclitaxel-induced death of HepG2 cells was also
studied.
Etoposide and Paclitaxel are Active and HIF-1 is Activated
Under Hypoxia in all Cell Types
Hypoxia is frequently described to inhibit the damaging effect of
chemotherapeutic agents [15]. In order to check if hypoxia inhibits
etoposide-induced DNA damage and/or paclitaxel-induced mi-
crotubule stabilisation or if it acts at a level downstream of the
damage caused by the drug, ATM (ataxia telangiectasia mutated)
phosphorylation was studied 1 hour after etoposide incubation
and the morphology of the microtubule fibres was studied after 16
hours paclitaxel exposure. Etoposide triggers cell death by
inducing double strand DNA breaks that lead to ATM activation.
The results showed that it indeed induced the phosphorylation of
ATM in the four cell types. No effect of hypoxia was observed on
the induction of P-ATM, even in HepG2 and MDA-MB231 cells
in which hypoxia decreased the etoposide-induced apoptosis
(Figure 2A). In HepG2 cells that are protected by hypoxia against
paclitaxel-mediated cell death, hypoxia did not seem to prevent
the formation of thick microtubule fibres induced by paclitaxel
Effect of Hypoxia on BCL-2 Family Proteins
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Figure 1. Effect of hypoxia on chemotherapeutic agents-induced cell death. HepG2, A549, U2OS, MDA-MB231, HT-29, Hep3B and PC-3 cells
were incubated under normoxia (21% O2) or hypoxia (1% O2) in the absence (CTL) or presence of etoposide (ETO), paclitaxel (TAX), cisplatin (CIS) or
camptothecin (CPT) for 16 (A, C, E, G, J) or 40 hours (B, D, F, H, I, K). The concentration used for each molecule is indicated in the graphs (in mM). (A, C,
E, G, J) Caspase-3/7 activity was assayed by measuring the fluorescence of free AFC released from the cleavage of the caspase-3/7 specific substrate
Ac-DEVD-AFC. Results are expressed in relative fluorescent units (RFU) as means 61 SD (n = 3). (B, D, F, H, I, K) LDH release was assessed. Results are
presented in percentages as means 61 SD (n = 3). (A-K) Statistical analysis was carried out with ANOVA 1. ns: non-significant; *: P,0.05; **: P,0.01;
***: P,0.001. Symbols above a normoxic column are a comparison with the normoxic control and symbols above a hypoxic column are a comparison
with the corresponding normoxic condition (with the same drug).
doi:10.1371/journal.pone.0047519.g001
Table 1. Effect of hypoxia on chemotherapeutic agents-induced cell death.
cell type p53
status
assay etoposide methotrexate paclitaxel cisplatin camptothecin
HepG2 wt Ap 50 mM no death at 10 mM no death at 5 mM 30 mM 0,5 mM
CD 50 mM no death at 50 mM 10 mM 30 mM 0,5 mM
A549 wt Ap 50 mM no death at 10 mM no death at 5 mM 75 mM 2 mM
CD 50 mM no death at 50 mM weak death at 10 mM 75 mM 2 mM
U2OS wt Ap 50 mM no death at 20 mM no death at 10 mM weak death at 100 mM 20 mM
CD 50 mM weak death at 50 mM no death at 10 mM no death at 100 mM 20 mM
MDA-MB231 R 281 K Ap 50 mM no death at 50 mM no death at 5 mM no death at 100 mM 2 mM
CD 50 mM no death at 50 mM weak death at 10 mM no death at 100 mM 2 mM
HT-29 R 273 HAp no death at 150 mM no death at 50 mM no death at 5 mM no death at 100 mM no death at 10 mM
CD 100 mM no death at 50 mM 10 mM weak death at 100 mM no death at 20 mM
Hep3B null Ap 100 mM no death at 50 mM no death at 5 mM 100 mM 10 mM
CD 100 mM no death at 50 mM 10 mM 100 mM 10 mM
PC-3 null Ap no death at 150 mM no death at 50 mM no death at 5 mM no death at 100 mM no death at 10 mM
CD no death at 50 mM no death at 50 mM no death at 5 mM no death at 100 mM no death at 10 mM
HepG2, A549, U2OS, MDA-MB231, HT-29, Hep3B and PC-3 cells were incubated under normoxia (N, 21% O2) or hypoxia (H, 1% O2) in the absence (control) or presence
of etoposide, methotrexate, paclitaxel, cisplatin or camptothecin. Apoptosis was assayed by measuring caspase-3/7 activity (Ap) and overall cell death was assessed by
measuring LDH release (CD) after 16 or 40 hour incubation respectively. Caspase-3/7 activity was assayed by measuring the fluorescence of free AFC released from the
cleavage of the caspase-3/7 specific substrate Ac-DEVD-AFC. The p53 status of each cell line is specified in the second column: wild type (wt), mutated or null. The
concentrations used for each molecule on each cell type are indicated. ‘‘weak death’’ means that some cell death (statistically different from the control) is sometimes
observed but not reproducible. A light grey cell indicates that hypoxia decreases drug-induced cell death; a dark grey cell indicates that hypoxia does not modify drug-
induced cell death; and a black cell indicates that hypoxia aggravates drug-induced cell death. hypoxia protect against cell death; hypoxia has no effect on cell death;
hypoxia aggravates cell death.
doi:10.1371/journal.pone.0047519.t001
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(Figure 2B and data not shown). Altogether, these results showed
that hypoxia protects cells downstream of the drug-induced
damage.
Many protective effects of hypoxia are mediated by the HIF-1
(hypoxia-inducible factor-1) transcription factor, which is a hetero-
dimer composed of one constitutively expressed subunit, HIF-
1beta, and one subunit stabilised only under hypoxic conditions,
HIF-1alpha [5]. We therefore investigated if this factor was
effectively activated by hypoxia in the cell lines in which hypoxia
does not have a protective effect (Figure 3). Hypoxia induced the
accumulation of HIF-1alpha but etoposide decreased this accu-
mulation in A549, MDA-MB-231 and Hep3B cells. In HepG2
cells, etoposide had no or a slight inhibiting effect according to the
experiment. The effect of etoposide on HIF-1alpha protein level
has already been observed [16]. As evaluated by luciferase
reporter, HIF-1 was active in each cell type during hypoxia and
this correlates with the mRNA abundance of two of its target genes
(LDHA and BNIP3).
In conclusion, the fact that hypoxia protects HepG2 and MDA-
MB231 cells against death but not A549 and Hep3B cells could
not be explained by a difference in etoposide- or paclitaxel-
induced damage or in HIF-1 activation.
Expression Profile of mRNAs Involved in Apoptosis
Results from Figure 2 suggest that the differential effect of
hypoxia on cell death occurs downstream of the induction of cell
damage. We thus hypothesised that hypoxia influences the signal
transduction pathways that trigger apoptosis. These pathways are
notably depending on p53 but also on other transcription factors.
Gene expression studies were thus performed to find genes whose
expression is differentially regulated by hypoxia in protected cells
in comparison to non-protected cells. Taqman Low Density
Arrays (Applied Biosystems) enabling the study of the abundance
of 93 mRNAs known to be involved in the apoptosis process (as
well as 3 housekeeping mRNAs) were used. The results are
presented as a heatmap in Figure 4 while the numerical values are
provided in Table S2. As expected, we observed the induction of
HIF-1 target genes (BNIP3, BNIP3L and GAPDH) after 16 hours
hypoxia in the four cell types. Induction of p53 target genes
(APAF-1, BAK1 and BAX) was observed in HepG2 and A549
cells after 16 hours etoposide incubation but not in the p53
mutated (MDA-MB231 cells) or null (Hep3B cells) cells. The p53
target gene PMAIP1 (NOXA) was induced by etoposide in all cell
types.
We then sought for genes whose expression profile is parallel to
the cell death profile in each of the four cell types, i.e. genes whose
expression was downregulated by hypoxia in HepG2 and MDA-
MB231 cells and unaffected or increased in A549 and Hep3B cells,
or the vice-versa. However, no such expression profile could be
observed. Interestingly, the expression of BCL2L11 (also called
BIM), BIK, CASP10, CASP3, DEDD2, NALP1 and TRADD was
decreased by hypoxia in etoposide-incubated HepG2 cells while
their expression was increased or unmodified in A549 cells,
correlating with the apoptotic profile of these two cell types.
Moreover, BIRC3 and MCL1 expression profile was inverse of the
apoptotic profile for HepG2 and A549 cells. The expression
profile of these genes was validated by single real-time RT-PCR
reactions. The results are presented as a heatmap in Figure 5 while
the numerical values are provided in Table S3. The profile of
BAK1, BAX, BBC3 (also called PUMA) and PMAIP1 (also called
NOXA) was also validated since they are well-known mediators of
the etoposide-induced cell death. Most of the results obtained
using Taqman Low Density Arrays were confirmed. It must
however be noted that the expression of nearly all studied genes
was decreased by hypoxia in all the etoposide-exposed cells.
Expression Profile of Proteins Involved in Apoptosis
In addition to be regulated by changes in gene expression, most
of the proteins involved in apoptosis are known to be also
regulated at the post-translational level [2]. Etoposide and
paclitaxel induce apoptosis by activating mainly the intrinsic
pathway [17,18,19], which is regulated by the abundance and the
subcellular localisation of proteins of the BCL-2 family. We
therefore studied the protein abundance of BCL-2 family proteins
in the four cell types as well as the subcellular localization of some
of them in HepG2 and A549 cells (Figure 6).
We first studied the pro-apoptotic BAX and BAK proteins.
BAX total protein level was slightly increased by etoposide in
HepG2, A549 and Hep3B cells but remained unaffected in MDA-
MB231 cells. Hypoxia slightly decreased BAX abundance in
HepG2 cells but had no effect in other cell types. This protein was
present in the MLP (mitochondria-lysosome-peroxisome) fraction
as well as in the cytosol of HepG2 and A549 cells. Etoposide
increased BAX abundance in the cytosol of HepG2 cells and in the
MLP fraction of A549 cells; this increase was prevented by
hypoxia. BAK total protein abundance was increased by etoposide
in HepG2, MDA-MB231 and Hep3B cells and this increase was
partly prevented by hypoxia in the three cell lines. In A549 cells,
no effect of hypoxia or etoposide was observed. BAK is only
present in the MLP fraction and its expression was increased by
etoposide in HepG2 and A549 cells and strongly decreased by
hypoxia. In conclusion, in HepG2 and MDA-MB231 cells in
which hypoxia protects against cell death, we observed that
hypoxia decreased the protein abundance of the BAK pro-
Figure 2. Effects of hypoxia on drug-induced damage. (A) Effect
of hypoxia, etoposide and paclitaxel on the abundance and phosphor-
ylation of ATM. HepG2, A549, MDA-MB231 and Hep3B cells were
incubated 1 hour under normoxia (N, 21% O2) or hypoxia (H, 1% O2) in
the presence or not (CTL) of etoposide (ETO, 100 mM in Hep3B cells and
50 mM in the other cell types) or paclitaxel (TAX, 10 mM) in HepG2 cells.
ATM and P-ATM were detected in nuclear protein extracts by western
blotting using specific antibodies. One experiment representative out
of three. Uncropped western blots are presented in Figure S1. (B) Effect
of hypoxia, etoposide and paclitaxel on microtubules. HepG2 cells were
incubated 16 hours under normoxia (21% O2) or hypoxia (1% O2) in the
presence or not of etoposide (50 mM) or paclitaxel (10 mM). After the
incubation, cells were fixed, permeabilised and stained for alpha-tubulin
using a specific antibody. Observation was performed using a confocal
microscope with a constant photomultiplier.
doi:10.1371/journal.pone.0047519.g002
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Figure 3. Effect of hypoxia, etoposide and paclitaxel on HIF-1alpha abundance and HIF-1 activity. HepG2, A549, MDA-MB231 and
Hep3B cells were incubated 16 hours under normoxia (N, 21% O2) or hypoxia (H, 1% O2) (A-D) in the presence or not (CTL) of etoposide (ETO, 100 mM
in Hep3B cells and 50 mM in the other cell types) or paclitaxel (TAX, 10 mM) in HepG2 cells (A, C, D). (A) HIF-1alpha was detected in total cell extracts
by western blotting using a specific antibody. Alpha-tubulin was used as loading control. One experiment representative out of three. Uncropped
western blots are presented in Figure S1. (B) Before incubation, cells were co-transfected with the pGL3-(PGK-HRE6)-tk-luc reporter plasmid encoding
the firefly luciferase and the pCMVß normalisation plasmid. Results are expressed as mean of the ratio between firefly luciferase activity and ß-
galactosidase activity61 SD (n = 3). Statistical analysis was carried out with ANOVA 1. ***: P,0.001. Symbols are a comparison between the normoxic
and hypoxic conditions of the same cell type. (C, D) After incubation, total RNA was extracted, submitted to reverse transcription and then to
amplification in the presence of SYBR Green and specific primers for BNIP3 (c) or LDHA (D). RPL13A was used as housekeeping gene for data
normalization. Data are given in fold-induction as the mean 61 SD (n = 3). Statistical analysis was carried out with ANOVA 1. ns: non-significant; *:
P,0.05; **: P,0.01; ***: P,0.001. Symbols above the hypoxic columns are a comparison with the corresponding normoxic condition (with the same
drug).
doi:10.1371/journal.pone.0047519.g003
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apoptotic protein. However, a decrease in BAK protein level was
also observed in Hep3B cells, which are not protected by hypoxia.
We then studied the abundance of anti-apoptotic proteins of the
BCL-2 family: BCL-2, BCL-w, BCL-xL and MCL-1. BCL-xL
protein level was increased by etoposide in A549 cells but, apart of
that, the BCL-2 and BCL-xL protein levels were not affected by
etoposide or hypoxia in the four cell lines. BCL-2 seemed not to be
expressed in Hep3B cells and was only detected in the MLP
fraction of HepG2 and A549 cells. Hypoxia decreased BCL-w
protein level in HepG2 cells but not in the other cell lines. Finally
the MCL-1 abundance was increased by etoposide in the four cell
lines (in both fractions in HepG2 and A549 cells) and decreased by
hypoxia in HepG2 and Hep3B cells. The results obtained by
subcellular fractionation correlated with the results obtained with
total extracts. In conclusion, in HepG2 cells in which hypoxia
protects against cell death we observed that, on the contrary to
what we could have expected, hypoxia decreased the protein
abundance of anti-apoptotic proteins such as BCL-w or MCL-1.
We also surprisingly observed that etoposide induced an increase
in the anti-apoptotic protein MCL-1 level in the four cell lines.
Figure 4. Effect of hypoxia, etoposide and paclitaxel on the mRNA expression level of genes involved in the apoptotic pathway.
Results were obtained using ‘‘TLDA Human Apoptosis Panel’’ (Applied Biosystems) (TLDA). HepG2, A549, MDA-MB231 and Hep3B cells were
incubated 16 hours under normoxia (N, 21% O2) or hypoxia (H, 1% O2) in the presence or not of etoposide (E, 100 mM in Hep3B cells and 50 mM in the
other cell types) or paclitaxel (T, 10 mM) in HepG2 cells. After incubation, total RNA was extracted, submitted to reverse transcription and then to
TLDA analysis. 18S was used as housekeeping gene for data normalization. Actual numerical values are provided in Table S2. Genes shown in bold are
genes whose expression was validated by qRT-PCT.
doi:10.1371/journal.pone.0047519.g004
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Figure 5. Effect of hypoxia, etoposide and paclitaxel on the mRNA expression level of genes involved in the apoptotic pathway.
HepG2, A549, MDA-MB231 and Hep3B cells were incubated 16 hours under normoxia (N, 21% O2) or hypoxia (H, 1% O2) in the presence or not of
etoposide (E, 100 mM in Hep3B cells and 50 mM in the other cell types) or paclitaxel (T, 10 mM) in HepG2 cells. After incubation, total RNA was
extracted, submitted to reverse transcription and then to real-time PCR in the presence of SYBR Green and specific primers. Actual numerical values
are provided in Table S3. Genes shown in bold are genes whose expression was assessed at the protein level by western blot analyses.
doi:10.1371/journal.pone.0047519.g005
Figure 6. Effect of hypoxia, etoposide and paclitaxel on the abundance and localisation of BCL-2 family proteins. HepG2, A549, MDA-
MB231 and Hep3B cells were incubated 16 hours under normoxia (N, 21% O2) or hypoxia (H, 1% O2) in the presence or not (CTL) of etoposide (ETO,
100 mM in Hep3B cells and 50 mM in the other cell types) or paclitaxel (TAX, 10 mM) in HepG2 cells. (A) Proteins were detected in total cell extracts by
western blotting, using specific antibodies. alpha-tubulin was used as loading control. One experiment representative out of three. Uncropped
western blots are presented in Figure S1. (B) After the incubation, subcellular fractionation was performed and proteins were detected in the MLP
(mitochondria-lysosome-peroxisome) and S (cytosolic) fractions by western blotting, using specific antibodies. TOM20 and b-actin were used as
loading controls for the MLP and S fractions respectively. One experiment representative out of three. Uncropped western blots are presented in
Figure S1.
doi:10.1371/journal.pone.0047519.g006
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Finally, we followed the abundance of the ‘‘BH3-only’’ proteins
BIM (3 isoforms), BID, PUMA, NOXA and BAD. In Hep3B cells,
NOXA protein was not detected and BAD protein was detected at
a very low level in comparison to the other cell types. Etoposide
increased BIMEL abundance in MDA-MB231 cells but, apart of
this, etoposide or hypoxia did not have marked effects on BIM
total protein levels. An increase in BIMEL abundance is sometimes
observed after incubation of A549 cells under hypoxia but this
observation was not always reproducible. BIM was only detected
in the MLP fraction and its abundance was decreased by hypoxia
for the 3 isoforms in HepG2 cells, by etoposide in A549 cells for
the BIMEL isoform and increased by paclitaxel in HepG2 cells for
the BIMEL isoform. In total extracts of HepG2 and A549 cells,
changes in electrophoretic migration in Tris-glycine SDS-PAGE
gels were detected. Indeed, when combined to etoposide, hypoxia
increased BIMEL migration while it was not the case in the 3 other
cell types. We hypothesised that hypoxia-induced changes in post-
translational modifications of BIMEL in HepG2 cells. Since ERK
(extracellular regulated kinase) and JNK (c-Jun N-terminal kinase)
are known to phosphorylate BIM [20,21], the effect of etoposide
and/or hypoxia on the phosphorylation of these two kinases was
investigated. The results showed that ERK phosphorylation was
enhanced by etoposide in A549 cells while JNK phosphorylation
was enhanced in HepG2 and in A549 cells. This phosphorylation
was inhibited by hypoxia in etoposide-stimulated HepG2 cells,
while it was only slightly inhibited in A549 cells (Figure S2). No
effect of etoposide and/or hypoxia could be detected in MDA-
MB231 or Hep3B cells.
BID abundance was slightly decreased by hypoxia in HepG2
cells but increased by hypoxia in MDA-MB-231 cells and
unaffected in the two other cell lines. tBID (truncated BID) was
not detected. PUMA abundance was increased by etoposide in
HepG2 cells alone and slightly decreased by hypoxia in HepG2
and Hep3B cells. PUMA was only detected in the cytosolic
fraction and its abundance was unaffected by etoposide or hypoxia
in HepG2 cells and a little bit decreased by hypoxia in A549 cells.
Etoposide strongly increased NOXA protein level in HepG2,
A549 and MDA-MB231 cells and this was partly prevented by
hypoxia in HepG2 and MDA-MB231 cells only. This protein
abundance profile is very interesting since it correlates with the
apoptotic profile. These observations were confirmed by the
results obtained by subcellular fractionation with NOXA being
only detected in the MLP fraction. We also observed that, in this
fraction, paclitaxel increased NOXA protein level. Etoposide
slightly increased BAD protein abundance in the four cell types
and hypoxia prevented this effect in HepG2 and Hep3B cell types
only. In HepG2 cells, BAD was mainly observed in the MLP
fraction with a strong decrease in its abundance under hypoxia. In
A549 cells, BAD was observed in both fractions and a slight
decrease in its abundance was also detected under hypoxia.
Role of BIM, NOXA and BAD in the Etoposide-induced
Apoptosis of HepG2 Cells
We observed that the abundance of several BH3-only proteins
was decreased by hypoxia in cells that are protected by hypoxia
against cell death. We thus studied the role of three of them in the
regulation of apoptosis for the following reasons: NOXA, since its
abundance varied in parallel to the apoptotic profile in the four
cell types; BIM, since it displayed a different electrophoretic
mobility under hypoxia vs normoxia in etoposide-exposed HepG2
cells; and BAD since its abundance was strongly decreased by
hypoxia in HepG2 cells. Specific siRNAs were used in HepG2
cells incubated in the presence of etoposide under normoxia or
hypoxia.
The efficiency of BIM, NOXA and BAD knockdown by siRNA
is shown in Figure S3. The effects of the knockdown of each of
these proteins were investigated on caspase-3/7 activity after 16
hours incubation and on LDH release after 40 hours incubation
(Figure 7). No effect of NOXA or BAD knockdown was observed
on apoptosis neither on overall cell death. However, BIM
knockdown induced a decrease in caspase-3/7 activity in cell
incubated with etoposide under normoxia as compared with
untransfected cells or with cells transfected with a negative control.
However, this decrease in caspase activity was not translated into
a decrease in overall cell death as measured by LDH release assay.
BIM is therefore probably partly involved in etoposide-induced
cell death but not alone. We therefore investigated the effect of the
combined silencing of BIM and NOXA proteins. BIM and
NOXA combined knockdown induced a significant decrease in
caspase-3/7 activity as well as in LDH release in cells incubated
with etoposide under normoxia as compared with untransfected
cells. We thus concluded that BIM and NOXA are important
mediators of etoposide-induced cell death and that the difference
in post-translational modification of BIM and the decrease in
NOXA protein level observed in hypoxic HepG2 cells at least in
part contribute to the decreased cell death observed under
hypoxia.
Since we already evidenced a potential role for p53 in the cell
behaviour observed under hypoxia in HepG2 cells [22], we
checked if BIM, NOXA and BAD expression were dependent on
p53 by using siRNAs directed against p53 (Figure 8). As expected,
p53 knockdown strongly decreased NOXA abundance, which is
known to be a p53 target gene, but did not affect BIM and BAD
abundance. Hypoxia therefore probably induced p53-dependent
and -independent pathways to modulate BH3-only protein
abundance and post-translational modifications.
Discussion
Hypoxic areas are frequently observed in solid tumours [23].
Due to uncontrolled tumour growth, cells in the centre of the
tumour are indeed often too far away from the blood vessels to
receive enough oxygen. Disorganised tumour vasculature further
impairs oxygen delivery to cancer cells. Severe hypoxia may
induce cell death, leading to necrotic areas within tumours. On the
contrary, mild hypoxia enhances tumour cell survival and induces
resistance to chemotherapy [7]. There is no gold standard for
measuring hypoxia. Eppendorf measurement of pO2 has been
used in human tumours but this method is invasive. Actual values
are available for head and neck, cervix and prostate carcinomas.
They usually range in between 1 and 10 mm Hg (0.14 to 1.4% O2)
(for a review see [24]). Actual values for other types of human
cancers are not available. Recent studies have focused on
molecular markers of hypoxia (HIF-1a or CAIX) that demonstrate
the presence of hypoxic areas within the tumours and not within
healthy tissues but these surrogate markers do not give absolute
values. Similarly, pimonidazole staining also gives an indication of
the presence of hypoxia but not absolute values. According to
these data, most of the work published in the literature is
performed at 1% O2 as the ‘‘standard’’ hypoxia. Moreover,
biological responses to hypoxia are optimal at 1% O2. This is for
example the case for the major regulator of these adaptive
responses, the transcription factor HIF-1. At much lower pO2
level, other responses are triggered that usually lead to cell death
(for reviews see [25,26,27]).
Cell responses to hypoxia obviously depend on the severity and
the duration of the decreased oxygen availability but also on the
cell type. For example, hypoxia (1% oxygen) protects HepG2 cells
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Figure 7. Effect of BH3-only proteins silencing on the etoposide-induced cell death. HepG2 cells were transfected with 50 nM BIM (A, B),
NOXA (C, D) or BAD (E, F) siRNAs, or 25 nM BIM combined with 25 nM NOXA (G, H), or 50 nM RISC-free (RF) control siRNA or left untransfected (CTL)
for 24 hours. 6 hours later (or 30 hours later for A and B), cells were incubated under normoxia (N, 21% O2) or hypoxia (H, 1% O2) with (ETO) or
without (CTL) etoposide (50 mM) for 16 (A, C, E, G) or 40 hours (B, D, F, H). (A, C, E, G) Caspase-3/7 activity was assayed by measuring the fluorescence
of free AFC released from the cleavage of the caspase-3/7 specific substrate Ac-DEVD-AFC. Results are expressed in relative fluorescence units (RFU)
as means 61 SD (n = 3). (B, D, F, H) LDH release was assessed. Results are presented in percentages as means 61 SD (n = 4, but n = 3 in B for the
condition HE CTL and in f for the condition H BAD). (A-H) Statistical analysis was carried out with ANOVA 1. ns: non-significant; *: P,0.05; **: P,0.01;
***: P,0.001.
doi:10.1371/journal.pone.0047519.g007
Effect of Hypoxia on BCL-2 Family Proteins
PLOS ONE | www.plosone.org 10 November 2012 | Volume 7 | Issue 11 | e47519
against etoposide-induced apoptosis as well as MDA-MB231 cells
against paclitaxel-induced apoptosis but has no effect or even
aggravates the apoptosis induced by etoposide in A549 and MCF-
7 cells as well as the epirubicin-induced apoptosis of MDA-MB231
cells [8,9,10]. In order to better understand why hypoxia
aggravates the chemotherapy-induced cell death in some cell
types while it protects against it in other cell types, we studied the
responses of seven cell types exposed to chemotherapy under
hypoxia. Cells from different organs and with different p53 status
were chosen. p53 mutation or inhibition is indeed a main cause of
chemoresistance [28] and it has been observed that hypoxia can
increase or decrease p53 abundance and/or activity [29]. p53
therefore probably plays an important role in the choice between
life and death of hypoxic cancer cells. Furthermore, the effects of
five different agents targeting different cell components to induce
cell death were compared. We observed that hypoxia generally
prevented drug-induced apoptosis, but hypoxia has sometimes no
effect, and in rare cases it could increase drug-induced cell death.
Interestingly, in most cases, the effect of hypoxia was the same for
all the drugs in one cell type. We also observed that hypoxia can
protect p53 wild-type cells as well as p53 mutated cells against cell
death.
In order to identify genes or proteins affected by hypoxia and
involved in the choice between life and death, four cell types
responding differently towards apoptosis under hypoxia were
selected: HepG2 (p53 wild-type cells that are protected by
hypoxia), A549 (p53 wild-type cells that are not protected by
hypoxia), MDA-MB231 (p53 mutated cells that are protected
by hypoxia) and Hep3B cells (p53 null cells that are not protected
by hypoxia). Death was induced by etoposide in the four cell lines.
In addition, the effects of paclitaxel were compared to the ones of
etoposide in HepG2 cells. We showed that hypoxia activated the
HIF-1 transcription factor in all cell lines and that etoposide and
paclitaxel were effective for inducing DNA and microtubule
damage respectively during hypoxia. The effect of hypoxia on cell
death therefore occurs downstream the initial damage and is not
dependent of a different activation of HIF-1. The study of the
abundance of 93 mRNAs known to be involved in the apoptosis
process showed that most of these genes were downregulated by
hypoxia in comparison to normoxia, in the presence of etoposide
in the four cell types. We found no candidate mRNA whose
variations of abundance in the different cells types could explain
the cell death profile for the four cell types.
Apoptosis is strongly regulated by the abundance and localisa-
tion of proteins of the BCL-2 family [1]. Hypoxia is known to
modulate the abundance and/or post-translational modifications
of most of these proteins. For example, hypoxia upregulates the
expression of anti-apoptotic genes and proteins of the family such
as the MCL-1 and BCL-xL genes in a manner dependent of HIF-
1, as well as BCL-2 [30–38]. Some reports described a hypoxia-
induced increase in BAX protein level while others observed
a decrease in BAX and/or BAK1 protein level
[22,33,37,39,40,41]. Several BH3-only proteins are also affected
by hypoxia. NOXA is a HIF-1 target gene and a mediator of
hypoxic cell death [42]. BIM and BMF expression can be
suppressed by hypoxia in a HIF-1-dependent manner [43]. BID
and BAD have been described to be upregulated or down-
regulated by hypoxia depending on the study [39,40,44]. Finally,
hypoxia reduces BAD phosphorylation on Ser112 but increases its
phosphorylation on Ser136 and Ser155 [45,46]. Since hypoxia has
frequently been described to affect BCL-2 family protein
abundance, their protein expression level was assessed by western
blot. The results are schematically represented in Figure 9A. As
expected, etoposide increased the abundance of various pro-
apoptotic proteins in the four cell types studied. It is for example
the case of BAX and/or BAK, or BAD and NOXA. However,
etoposide also induced the expression of the anti-apoptotic protein
MCL-1. Our results show how much cell types can differently
react to similar hypoxic conditions. In HepG2 cells that are
markedly protected against cell death by hypoxia, hypoxia
decreased the abundance of nearly all the pro-apoptotic BCL-2
family proteins while none of them are decreased in A549 cells
that are not protected by hypoxia. We could therefore hypothesize
that it is this differential effect of hypoxia on BCL-2 family protein
abundance that is responsible for the different behaviour of these
two cell types about apoptosis during hypoxia. For MDA-MB231
and Hep3B cells, such a hypothesis cannot be put forth. Indeed, in
both cell types, hypoxia decreased the abundance of some pro-
apoptotic proteins while their apoptotic response is different. The
study of the abundance of BCL-2 family proteins is therefore not
sufficient to understand the general apoptotic behaviour of a given
cell type. It is however interesting to note that the NOXA
upregulation by etoposide was partly prevented by hypoxia in cells
that are protected against cell death (HepG2 and MDA-MB231
cells) while this was not the case in cells that are not protected by
hypoxia (A549 and Hep3B cells, NOXA being not expressed in
this latter cell type). The outcome of the network of interactions
between proteins of the BCL-2 family evidently does not only
depend on their abundance but also on their subcellular
localisation, on their post-translational modifications and on
binding partners. Moreover, BCL-2 family proteins are not the
only regulators of apoptosis. Downstream regulation can also
occur, such as by regulation of inhibitors of caspases for example.
With the aim to go further in the understanding of this complex
network, we then focused on HepG2 cells that are strongly
protected by hypoxia against etoposide-induced cell death. We
chose to study the role of NOXA, BIM and BAD in the etoposide-
induced apoptosis. These three proteins are indeed downregulated
or modified under hypoxia. Etoposide induces DNA damage and
is therefore known to induce cell death mainly via the p53
pathway. p53-induced apoptosis is principally triggered by PUMA
and NOXA overexpression [47,48]. Here we showed that both
Figure 8. Effect of p53 silencing on the expression of BIM,
NOXA and BAD. HepG2 cells were transfected with 50 nM p53 siRNA
(p53) or non-targeting control siRNA (NT) or left untransfected (/) for 24
hours. Minimum 6 hours later, cells were incubated under normoxia (N,
21% O2) or hypoxia (H, 1% O2) with (ETO) or without (CTL) etoposide
(50 mM) for 16 hours. Proteins were detected in total cell extracts by
western blotting, using specific antibodies. ß-actin was used as loading
control. One experiment representative out of three. Uncropped
western blots are presented in Figure S1.
doi:10.1371/journal.pone.0047519.g008
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proteins are indeed upregulated by etoposide in HepG2 cells.
However, unexpectedly, PUMA was not localised in the
mitochondria-containing fraction. It is therefore possible that it
does not initiate cell death. Etoposide also induced cell death and
NOXA upregulation in p53 mutated or null cells. NOXA
upregulation can be induced by p53-independent pathway such
as via p73 [49,50]. However, in etoposide-incubated HepG2 cells,
NOXA knockdown did not decrease cell death. Besides the well-
known role of NOXA, BIM has also been described to play a role
in DNA damage-induced apoptosis [51]. The difference in
electrophoretic mobility of BIMEL between normoxia and hypoxia
in the presence of etoposide probably reveals a change in post-
translational modification that could correspond to a loss of
phosphorylation during hypoxia. Isoelectric focusing two di-
mensional (IEF-2D) gel analysis of endogenously expressed BIMEL
showed at least 5 distinct spots in MCF-7 cells, which supposed
that this protein is indeed subject to various post-translational
modifications [52]. The main kinases known to phosphorylate
BIMEL are ERK1/2 and JNK. Following activation of the ERK1/
2 pathway, BIMEL could be phosphorylated on at least 3 residues
and this would induce its dissociation from the BCL-2 family
members, its ubiquitination and its degradation by the proteasome
[20,21]. The role of JNK-mediated phosphorylation of BIMEL is
still controversial since it can induce its degradation by the
proteasome while in most cases it would rather enhance its pro-
apoptotic activity notably by inducing a decrease in its affinity for
DLC1 (dynein light chain 1) - a protein that can sequester BIMEL
in basal conditions – allowing BIMEL to play a role at the
mitochondrial level, and an increased interaction with BCL-2
[20,21]. However, ERK1/2 and JNK have some common
phosphorylation sites and it seems that BIMEL stability and
activity depends on a complex phosphorylation code that is cell
type dependent [53,54]. Other kinases have also been described to
target BIMEL. It is for example the case for AKT, RSK 1/2
(ribosomal protein S6 kinase), ERK5 or CDK1 (cyclin-dependent
kinase 1), which all promote cell survival either by inducing its
sequestration away from the mitochondria or either by inducing its
degradation [55,56,57,58]. It is also the case for PKA (protein
kinase A) or p38-MAPK (mitogen-activated protein kinase), which
induce its stabilisation or enhance its pro-apoptotic activity
[53,59]. BIMEL seems to be phosphorylated since its electropho-
retic mobility was slower for normoxic HepG2 cells than for
hypoxic cells. We showed that BIM knockdown decreased
caspase-3/7 activity in HepG2 cells stimulated with etoposide
without affecting the overall cell death as measured by LDH
release. We hypothesize that in etoposide-stimulated HepG2 cells,
BIMEL is phosphorylated and is active in promoting apoptosis.
This phosphorylation would be absent in hypoxic HepG2 cells,
either due to a decreased activation of the kinase(s) or to the
activation of a phosphatase such as PP2A (protein phosphatase 2A)
which is known to dephosphorylate BimEL [52]. Both hypotheses
could be right since PP2A is sometimes activated by hypoxia
[60,61] and since we observed that JNK phosphorylation was
markedly inhibited by hypoxia in etoposide-stimulated HepG2
cells, while it was only very slightly inhibited in A549 cells. Finally,
a major role of BAD in DNA-damage induced cell death is usually
not described and we observed no effect of its knockdown on
etoposide-induced cell death. Though NOXA knockdown had no
impact on etoposide-induced cell death and BIM knockdown only
affected the caspase activity but not the overall cell death, the
combined loss of BIM and NOXA induced a decrease in caspase-
3/7 activity and also induced a decrease in LDH release in cells
incubated with etoposide under normoxia. These observations on
HepG2 cell death are similar to the ones obtained by Kirschnek
et al. when studying the spontaneous death of neutrophils
obtained from knockout mice. They indeed observed no effect of
BIM or NOXA single knockout on neutrophil cell death while the
combined knockdown of these two proteins strongly protected
these cells against cell death [3]. The difference in post-trans-
lational modification of BIM and the decrease in NOXA protein
level observed in hypoxic HepG2 cells therefore probably
contribute to the decreased cell death observed under hypoxia.
Our results suggest that BAK, BIM, NOXA and MCL-1 are the
main mitochondrial players of etoposide-induced cell death that
are regulated by hypoxia. Indeed, we previously evidenced that
BAK is an important component of etoposide-induced cell death
in HepG2 cells [22] and we here showed the involvement of BIM
and NOXA. It is known that BCL-xL and MCL-1 are the main
inhibitors of BAK, that the inhibition by MCL-1 can be relieved
by NOXA [62], and that BIM can act as a direct activator of BAK
[63]. Therefore, we hypothesize (Figure 9B) that, in control cells,
a part of the BAK pool is inhibited by MCL-1. When the cells are
incubated in the presence of etoposide, NOXA and BAK are
upregulated and BIM is activated. NOXA inhibits MCL-1 and
BAK is activated by BIM to induce cell death. In etoposide-
incubated cells, NOXA knockdown has no effect on cell death
since the free BAK pool is sufficient to promote cell death when it
is activated by BIM. However, the absence of BIM partly
prevented caspase activation. In cells in which BIM is silenced,
NOXA knockdown decreased cell death since a part of BAK pool
is inhibited by MCL-1 and since the BAK free pool is not activated
by BIM. Hypoxia inhibited the etoposide-induced induction of
BAK and NOXA as well as changed BIM post-translational
modifications. These effects inhibit cell death since there is
a smaller amount of BAK, that is not activated by BIM and that is
partly inhibited by MCL-1, although MCL-1 abundance is also
decreased.
The p53 protein level profile corresponds to the apoptotic
profile of HepG2 and A549 cells [8] and p53 is probably an
important node in the decision between life and death for hypoxic
cancer cells [29]. Here, we showed that, in etoposide-stimulated
HepG2 cells, NOXA abundance was dependent of p53 but that
this was not the case for BIM and BAD abundance. These results
correlate with the fact that NOXA is a p53-target gene [64], that
BIM is probably not [65], while BAD is regulated by p53 in some
cell types but not all [66]. We conclude therefore that hypoxia
induced p53-dependent and -independent pathways to modulate
Figure 9. Schematic representation of the effects of hypoxia on the etoposide-induced effects on BCL2-family proteins. (A)
Schematic representation of the results obtained in figure 4. Anti-apoptotic proteins are represented outlined in green and pro-apoptotic proteins
are outlined in red. The activation arrows and inhibition signs come from the hypothesis of the interactions between BCL-2 family proteins as
explained in [69,70]. The proteins whose abundance is increased by etoposide are outlined with a thicker line. A yellow filling represents that, in the
presence of etoposide, hypoxia decreased the abundance of the protein (or the death) as compared to normoxia. A pink filling represents that, in the
presence of etoposide, hypoxia increased the abundance of the protein as compared to normoxia. (B) Schematic representation of the hypothetic
relations between BIM, BAK, MCL-1 and NOXA. These possible mechanisms are represented for normoxic (21% O2) or hypoxic (1% O2) HepG2 cells
incubated with or without etoposide (ETO; 50 mM) and with or without silencing (2) of NOXA and/or BIM. The hypothetic relations between these
proteins are explained in details in the text. Anti-apoptotic proteins are represented outlined in green and pro-apoptotic proteins are outlined in red.
doi:10.1371/journal.pone.0047519.g009
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BH3-only protein abundance, post-translational modifications as
well as cell death.
In addition to modulate apoptosis, hypoxia may also influence
autophagy, also called programmed type II cell death. Autophagy
is a tightly regulated process by which selected components of a cell
are degraded. It primarily functions as a cell survival adaptive
mechanism during stress conditions. However, prolonged un-
resolved damage can also lead to cell death through excessive
autophagy. Accumulating data indicate a role for autophagy in
chemotherapy-induced cancer cell death [67]. Autophagy most
commonly dampens treatment efficacy as it has been shown in vitro
for different cell types. Hypoxia also triggers autophagy that
participates to chemoresistance, notably by inducing BNIP3
expression [68]. A third adaptive response possibly triggered by
hypoxia is the unfolded protein response. However, its possible
role in chemoresistance is not yet well defined [26].
We showed that hypoxia affects the cell death of various cell
types in a very different manner, influencing or not the
chemotherapeutic efficacy. Hypoxia also modulates most proteins
of the BCL-2 family in a cell type-dependent manner. In HepG2
cells that are protected by hypoxia against etoposide-induced cell
death, many proteins of this family are downregulated, such as
NOXA, or have different post-translational modifications, such as
BIM. The combined loss of BIM and NOXA activity during
hypoxia could partly account for chemoresistance. Hypoxia-
induced chemoresistance is still an important problem for the
success of therapies. Our results emphasize the need for a better
comprehension of the factors causing these different cell
behaviours in order to overcome the hypoxia-induced chemore-
sistance and ameliorate cancer therapy.
Supporting Information
Figure S1 Uncropped western blots for Figures 2, 3, 6
and 8 and for Figures S2 and S3.
(PDF)
Figure S2 Effect of hypoxia, etoposide and paclitaxel on
JNK and ERK phosphorylation. HepG2, A549, MDA-
MB231 and Hep3B cells were incubated 16 hours under normoxia
(N, 21% O2) or hypoxia (H, 1% O2) in the presence or not (CTL)
of etoposide (ETO, 100 mM in Hep3B cells and 50 mM in the
other cell types) or paclitaxel (TAX, 10 mM) in HepG2 cells.
Proteins were detected in total cell extracts by western blotting,
using specific antibodies. Uncropped western blots are presented
in the supplementary figure 1.
(PDF)
Figure S3 Effect of BH3-only proteins silencing on their
mRNA and protein levels. HepG2 cells were transfected with
50 nM BIM (a, f), NOXA (b, g) or BAD (c, h) siRNAs, or 25 nM
BIM combined with 25 nM NOXA siRNAs (d, e, i), or 50 nM
RISC-free (RF) control siRNA or left untransfected (/) for 24
hours. 6 hours later (or 30 hours later for a and f), cells were
incubated under normoxia (N, 21% O2) or hypoxia (H, 1% O2)
with (ETO, E) or without (CTL) etoposide (50 mM) for 16 hours.
(a, b, c, d, e) After incubation, total RNA was extracted,
submitted to reverse transcription and to amplification in the
presence of SYBR Green and specific primers (RT-PCR).
RPL13A was used as housekeeping gene for data normalization.
Data are given in fold induction (n= 1). (f, g, h, i) Proteins were
detected in total cell extracts by western blotting, using specific
antibodies. alpha-tubulin was used as loading control. Uncropped
western blots are presented in Figure S1.
(PDF)
Table S1 Sequences of the primers used for RT-real-
time PCR.
(PDF)
Table S2 Effect of hypoxia, etoposide and paclitaxel on
the mRNA expression level of genes involved in the
apoptotic pathway. Results were obtained using ‘‘TLDA
Human Apoptosis Panel’’ (Applied Biosystems) (TLDA). HepG2,
A549, MDA-MB231 and Hep3B cells were incubated 16 hours
under normoxia (N, 21% O2) or hypoxia (H, 1% O2) in the
presence or not of etoposide (E, 100 mM in Hep3B cells and
50 mM in the other cell types) or paclitaxel (T, 10 mM) in HepG2
cells. After incubation, total RNA was extracted, submitted to
reverse transcription and then to TLDA analysis. 18S was used as
housekeeping gene for data normalization. Data are given in fold-
induction. Grey cell notify that the Ct value was .35 and should
therefore not be considered as quantitative. ‘‘-’’ non expressed or
not possible to calculate a fold change because the mRNA is not
expression in controle cells. Genes shown in bold are genes whose
expression was validated by qRT-PCT.
(PDF)
Table S3 Effect of hypoxia, etoposide and paclitaxel on
the mRNA expression level of genes involved in the
apoptotic pathway. Comparison of results obtained using
‘‘TLDA Human Apoptosis Panel’’ (Applied Biosystems) (TLDA)
and single real-time RT-PCR reactions (RT-PCR). HepG2, A549,
MDA-MB231 and Hep3B cells were incubated 16 hours under
normoxia (N, 21% O2) or hypoxia (H, 1% O2) in the presence or
not of etoposide (E, 100 mM in Hep3B cells and 50 mM in the
other cell types) or paclitaxel (T, 10 mM) in HepG2 cells. After
incubation, total RNA was extracted, submitted to reverse
transcription and then to TLDA analysis or to amplification in
the presence of SYBR Green and specific primers (RT-PCR). 18S
and RPL13A were used as house keeping genes for data
normalization of TLDA and single real-time RT-PCR reactions
respectively. Data are given in fold-induction as the mean 61 SD
(n = 3) is provided for single real-time RT-PCR reactions. Refer to
Table S2 for complete TLDA results. Grey cell notify that the Ct
value was .35 and should therefore not be considered as
quantitative. ‘‘-’’ non expressed or not possible to calculate a fold
change because the mRNA is not expression in control cells.
Genes shown in bold are genes whose expression was assessed at
the protein level by western blot analyses.
(PDF)
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